Hypermarcas (OTCMKTS:HYPMY) Shares Down 8.8% – Here’s Why

Shares of Hypermarcas (OTCMKTS:HYPMY) dropped 8.8% during mid-day trading on Wednesday. The company traded as low as $3.92 and last traded at $4.2142. 4,018 shares were traded during mid-day trading, a decline of 79% from the average session volume of 19,450 shares. The stock had previously closed at $4.62.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy”.

Hypermarcas Stock Up 5.1%

The firm’s 50-day moving average price is $4.33 and its two-hundred day moving average price is $4.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.26 and a current ratio of 1.86. The firm has a market cap of $3.35 billion, a PE ratio of 9.52 and a beta of 0.65.

Hypermarcas (OTCMKTS:HYPMY) last posted its earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 12.68%. As a group, equities research analysts expect that Hypermarcas will post 0.51 EPS for the current fiscal year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer healthcare company that developed, manufactured and marketed pharmaceutical and healthcare products. Its portfolio included over-the-counter medicines, prescription products, vitamins and other consumer health brands sold through pharmacies and retail channels.

The company was historically associated with well-known Brazilian brands such as Benegrip, Biotônico Fontoura, Doril, Engov and Epocler. Hypermarcas also previously operated in personal care, beauty, household cleaning and other consumer categories, but divested many of those businesses as it concentrated on pharmaceuticals and healthcare.

In 2018, Hypermarcas changed its corporate name to Hypera SA, adopting the Hypera Pharma identity.